<DOC>
	<DOCNO>NCT00810680</DOCNO>
	<brief_summary>The purpose study determine whether Valproic acid , single agent effective treatment Chronic Lymphocytic Leukemia relapse refractory therapy standard drug .</brief_summary>
	<brief_title>Study Efficacy Safety Valproic Acid Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Chronic lymphocytic leukemia ( CLL ) disease characterize prolonged clinical course . Though various drug alkylating agent , antimetabolites fludarabine target antibody rituximab effective condition , relapse frequent cure rare . There exist subset CLL patient refractory many first line agent . Though one mentioned class drug substitute patient relapsed refractory disease , therapy conclusively proven survival advantage condition . The cost toxicity add burden therapy . Valproic acid well studied drug use treatment epilepsy 30 year . It well document side effect profile , generally well tolerated inexpensive . Recently , show inhibitor enzyme , Histone de-acetylase ( HDAC ) . Inhibition HDAC promote apoptosis , could lead death CLL cell harbor defective apoptotic mechanism . In vitro study prove ability therapeutic concentration Valproic acid achieve cell kill culture CLL cell . This study aim identify whether valproic acid , use standard dos single agent activity CLL ass tolerance patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Active CLL ( define National Cancer Institute Working Group ) Patients must receive least one prior therapy CLL treat nucleoside analogue . Age 18 year old . Good general condition define Eastern cooperative oncology group performance status ( ECOGPS ) &lt; /=2 . Absolute neutrophil count &gt; 1500/cmm platelet count &gt; 30,000/cmm unless low count due disease . Adequate liver function ( bilirubin &lt; 2 mg/dL , ASTorALT &lt; 3Xthe upper limit normal ) renal function ( serum creatinine &lt; 2 mg/dL creatinine clearance &gt; 30 mL/min ) unless abnormality result disease involvement . Full recovery previous treatment . Any therapy CLL within 4 week initiate treatment study . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>valproic acid</keyword>
	<keyword>valproate</keyword>
</DOC>